Pfizer sues drug companies over Enbrel biosimilar

Ashurst 2022-05-10 11:38 pm By Cat Fredenburgh | Melbourne

Please login to bookmark

Pharmaceutical giant Pfizer has fired off a lawsuit against four drug companies for allegedly infringing one of its patents for biologic Enbrel by selling a biosimilar of the blockbuster arthritis drug in Australia.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au